Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy

• Published in: Breast cancer research and treatment 2009-10, Vol.117 (3), p.497-504
• Main Authors: Papi, Laura, Putignano, Anna Laura, Congregati, Caterina, Zanna, Ines, Sera, Francesco, Morrone, Doralba, Falchetti, Mario, Turco, Marco Rosselli Del, Ottini, Laura, Palli, Domenico, Genuardi, Maurizio
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological and medical sciences; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms, Male - genetics; Cancer research; DNA Mutational Analysis; Female; Female genital diseases; Founder Effect; Genes, BRCA1; Genetic disorders; Gynecology. Andrology. Obstetrics; Haplotypes; Humans; Italy; Male; Mammary gland diseases; Medical sciences; Medicine; Medicine & Public Health; Microsatellite Repeats - genetics; Middle Aged; Mutation; Oncology; Ovarian cancer; Pedigree; Preclinical Study; Tumors
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-008-0190-3

Background Germline mutations in the BRCA1 and BRCA2 tumour-suppressor genes predispose to early-onset breast and ovarian cancer. Although both genes display a highly heterogeneous mutation spectrum, a number of alterations recur in some populations. Only a limited number of founder mutations have been identified in the Italian population so far. Objective To investigate the spectrum of BRCA1/BRCA2 mutations in a set of families originary from the Central-Eastern part of Tuscany and to ascertain the presence of founder effects. We also wanted to approximate the age of the most frequent BRCA1 founder mutation. Results Overall, four distinct BRCA1 mutations accounted for a large fraction (72.7%) of BRCA1-attributable hereditary breast/ovarian cancer in families originary from this area. We identified common haplotypes for two newly recognised recurrent BRCA1 mutations, c.3228_3229delAG and c.3285delA. The c.3228_3229delAG mutation was estimated to have originated about 129 generations ago. Interestingly, male breast cancer cases were present in 3 out of 11 families with the c.3228_3229delAG mutation. Conclusions The observation that a high proportion of families with BRCA1 alterations from Central-Eastern Tuscany harbours a limited number of founder mutations can have significant impact on clinical management of at risk subjects from this area. In addition, the identification of a large set of families carrying an identical mutation that predisposes to breast and ovarian cancer provides unique opportunities to study the effect of other genetic and environmental factors on penetrance and disease phenotype.